We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
-3.24%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$73.5B
AUM Growth
-$7.73B
(-9.5%)
Cap. Flow
-$10.4B
Cap. Flow
% of AUM
-14.12%
Top 10 Holdings %
Top 10 Hldgs %
24.14%
Holding
2,549
New
227
Increased
861
Reduced
712
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PPL
PPL Corp
PPL
|
+$301M |
| 2 |
Estee Lauder
EL
|
+$252M |
| 3 |
Boeing
BA
|
+$251M |
| 4 |
Kenvue
KVUE
|
+$174M |
| 5 |
Fidelity National Information Services
FIS
|
+$166M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$547M |
| 2 |
Union Pacific
UNP
|
+$459M |
| 3 |
Pinnacle West Capital
PNW
|
+$203M |
| 4 |
Wells Fargo
WFC
|
+$199M |
| 5 |
Bank of America
BAC
|
+$199M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.75% |
| 2 | Healthcare | 13.74% |
| 3 | Financials | 13.36% |
| 4 | Industrials | 11.58% |
| 5 | Consumer Discretionary | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DEN
1726
DELISTED
Denbury Inc.
DEN
| $38K | ﹤0.01% |
392
+212
| +118% | +$19.2K |
|
|
MACK
1727
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $38K | ﹤0.01% |
3,123
| – | – |
|
1728
Vita Coco
COCO
$3.71B
| $37K | ﹤0.01% |
1,454
| – | – |
|
1729
Dillards
DDS
$9.64B
| $37K | ﹤0.01% |
113
-125
| -53% | -$41.3K |
|
1730
Edgewell Personal Care
EPC
$1.3B
| $37K | ﹤0.01% |
1,011
-326
| -24% | -$12.6K |
|
1731
EyePoint Inc
EYPT
$1.08B
| $37K | ﹤0.01% |
4,658
| – | – |
|
1732
Freedom Holding
FRHC
$9.39B
| $37K | ﹤0.01% |
445
-7,624
| -94% | -$646K |
|
1733
Legend Biotech
LEGN
$3.73B
| $37K | ﹤0.01% |
569
+25
| +5% | +$1.74K |
|
1734
Maravai LifeSciences
MRVI
$922M
| $37K | ﹤0.01% |
3,814
+159
| +4% | +$1.75K |
|
1735
Saic
SAIC
$5.25B
| $37K | ﹤0.01% |
+355
| New | +$40.9K |
|
1736
Vivid Seats
SEAT
$88.6M
| $37K | ﹤0.01% |
+296
| New | +$43.6K |
|
|
AXNX
1737
DELISTED
Axonics, Inc. Common Stock
AXNX
| $37K | ﹤0.01% |
674
| – | – |
|
1738
Cathay General Bancorp
CATY
$4.26B
| $36K | ﹤0.01% |
1,056
| – | – |
|
1739
Employers Holdings
EIG
$908M
| $36K | ﹤0.01% |
+907
| New | +$35.1K |
|
1740
FNB Corp
FNB
$6.75B
| $36K | ﹤0.01% |
3,422
| – | – |
|
1741
Omega Flex
OFLX
$312M
| $36K | ﹤0.01% |
+461
| New | +$39.8K |
|
1742
Selective Insurance
SIGI
$5.77B
| $36K | ﹤0.01% |
+355
| New | +$35.6K |
|
1743
Wave Life Sciences
WVE
$1.19B
| $36K | ﹤0.01% |
6,373
+333
| +6% | +$1.52K |
|
1744
Editas Medicine
EDIT
$445M
| $35K | ﹤0.01% |
4,595
+2,062
| +81% | +$17.7K |
|
1745
Evolution Petroleum
EPM
$127M
| $35K | ﹤0.01% |
5,209
-1,547
| -23% | -$13.1K |
|
1746
First Watch Restaurant Group
FWRG
$768M
| $35K | ﹤0.01% |
2,047
+1,107
| +118% | +$20.4K |
|
1747
Oppenheimer Holdings
OPY
$1.22B
| $35K | ﹤0.01% |
936
| – | – |
|
1748
Orrstown Financial Services
ORRF
$845M
| $35K | ﹤0.01% |
1,667
+915
| +122% | +$19.9K |
|
1749
STAAR Surgical
STAA
$1.15B
| $35K | ﹤0.01% |
889
-1,429
| -62% | -$66.9K |
|
1750
Turning Point Brands
TPB
$1.7B
| $35K | ﹤0.01% |
1,538
+382
| +33% | +$9.31K |
|
Similar funds
QCM
Lazard Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Lazard Asset Management held 2,549 positions worth $73.5B, down 9.5% from $81.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $10.4B in Q3 2023, closing 243 positions and reducing 712 holdings. Its most notable exit was Littelfuse, an estimated $24.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lazard Asset Management opened a new position in ScottsMiracle-Gro worth $28.3M.
- Lazard Asset Management's largest Q3 2023 buy was ScottsMiracle-Gro: 548,310 shares worth $28.3M.
- Lazard Asset Management added most to PPL Corp in Q3 2023, an estimated $301M increase.
- Lazard Asset Management's biggest Q3 2023 reduction was Johnson & Johnson, cutting an estimated $547M.
- Lazard Asset Management fully exited Littelfuse in Q3 2023, selling an estimated $24.3M.
- Lazard Asset Management's ten largest holdings make up 24% of its $73.5B portfolio in Q3 2023.
- Lazard Asset Management opened 227 new positions and closed 243 in Q3 2023.
- Lazard Asset Management's portfolio value fell 9.5% quarter-over-quarter to $73.5B.
Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.